Liraglutide, a human GLP-1 analogue, is already FDA approved for the treatment of obesity (Saxenda®) and type 2 diabetes (Victoza®) [45, 46], and is in addition to it's well-described incretin effects [47], also reported to improve liver enzymes, oxidative stress, and steatosis [20, 26, 30, 31, 37, 48]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.